No Data
High Insider Ownership Growth Stocks On The ASX In June 2024
Express News | Cantor Fitzgerald Reiterates Overweight on Mesoblast
Mesoblast Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/04/2024 — Cantor Fitzgerald Reiterates → Overweight 09/21/2023 133.52% Cantor Fitzgerald → $17 Reitera
Mesoblast Targets FDA Approval With Ryoncil
Mesoblast Projects Future Amidst Uncertainties
ASX Growth Leaders With High Insider Ownership Explored